Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Continuing Medical Education

Executive Summary

The American Academy of Family Practitioners is discussing implementation and "possible additions" to AMA's recently adopted CME guidelines. According to AAFP bylaws, the ethics and guidelines of AMA automatically become those of AAFP. At a two-day meeting in Kansas City June 18-19, AAFP sought input from industry, physician groups, and FDA on the current standards of CME. Participating in the open panel discussion was FDA Branch Chief, Drug Advertising Regulation Branch Kenneth Feather. He was joined by representatives from the American College of Physicians, the American Academy of Pediatrics, ACCME, PMA, Burroughs- Wellcome, Marion Merrell Dow, and Upjohn. An AAFP spokesperson said that the committee "discussion was about whether XYZ activity was in line" with AMA guidelines. This was the first of two meetings on CME, which AAFP described as "the discovery phase." The committee's findings will be presented to AAFP's board of directors and guidelines will ultimately be ratified at AAFP's Congress of Delegates.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts